International Edition
Latest News
Health

Mepolizumab Cuts High-Dose Steroid Days in COPD on Triple Therapy

“Mepolizumab as add-on to inhaled triple therapy may help reduce corticosteroid burden in COPD, particularly complications and poor outcomes associated with short-term high-dose courses,” said Nicola A. Hanania, director of the Airway Clinical Research Center at Baylor College…

Older adult holds an inhaler during a COPD treatment consultation

“Mepolizumab as add-on to inhaled triple therapy may help reduce corticosteroid burden in COPD, particularly complications and poor outcomes associated with short-term high-dose courses,” said Nicola A. Hanania, director of the Airway Clinical Research Center at Baylor College of Medicine, according to Medscape.

Adding the monoclonal antibody to standard treatment significantly lowers annual systemic corticosteroid exposure in patients with type 2 inflammation, according to data presented at the CHEST annual meeting in Phoenix on October 20.

Researchers pooled results from the METREX, METREO, and MATINEE phase 3 trials to evaluate 2,089 patients aged 40 or older. All participants had a history of exacerbations and were receiving inhaled triple therapy without a current asthma diagnosis. Of the total cohort, 1,043 patients received 100 mg of subcutaneous mepolizumab every four weeks for 52 weeks, with the MATINEE trial extending up to 104 weeks for some participants; 1,046 patients received a placebo.

The analysis demonstrated that mepolizumab, which targets interleukin-5, reduced the cumulative amount of systemic corticosteroids required over one year. These reductions were consistent across two different blood eosinophil count (BEC) thresholds used during patient screening.

Eosinophil Threshold Mepolizumab Exposure Placebo Exposure
At least 150 cells/µL 434.64 mg 609.95 mg
At least 300 cells/µL 354.28 mg 551.52 mg

Patients treated with mepolizumab also spent fewer days on high-dose systemic corticosteroids compared to those in the placebo group. Those receiving placebo spent 5.9% of their days (11,850 total days) on high-dose corticosteroids, compared to 4.5% of days (8,403 total days) for the mepolizumab group.

In the subgroup with a BEC of at least 300 cells/µL, 631 participants (55%) received corticosteroids for any reason. Those in the mepolizumab group spent 90.8% of days steroid-free, compared to 88.9% for placebo.

“Mepolizumab is a humanized monoclonal antibody specifically targeting IL-5 [interleukin-5], approved in COPD with an eosinophilic phenotype,” Hanania said.

“Mepolizumab has shown corticosteroid-sparing properties in other approved eosinophilic indications,” Hanania said.

The pooled analysis of the three trials evaluated the percentage of days patients remained free of systemic corticosteroids.

In the subgroup of 1,144 participants with a blood eosinophil count of at least 300 cells/μL, 631 individuals—or 55% of that cohort—required corticosteroids for any reason during the study period. Within this specific group, those receiving mepolizumab spent 3.8% of their time on high-dose therapy, whereas the placebo group required high-dose corticosteroids on 5.1% of their days.

Nicola A. Hanania serves as the director of the Airway Clinical Research Center at Baylor College of Medicine, where his expertise centers on developing and testing new interventions to eliminate the burden of asthma and COPD. His extensive research background includes leading investigations into the clinical implications of respiratory drug efficacy and managing chronic disease in diverse patient cohorts.

Recognized for his contributions to the field, Hanania was awarded the Career Investigator Award (K23) by the National Institute of Health, NHLBI, from 2005 to 2009. Additionally, his commitment to advancing the understanding of COPD pathogenesis and treatment was honored in 2016 when he received the Thomas L. Petty, MD, Master ACCP Memorial Lectureship from the American College of Chest Physicians.

While the therapy shows potential for lowering steroid reliance, whether these reductions directly correlate to fewer corticosteroid-related complications remains an open question. Clinicians managing patients with a history of exacerbations now have an estimate of how much systemic corticosteroid exposure may differ when adding the monoclonal antibody to their current regimen.

About the author: Health Desk

Health Desk at Archynewsy.